|
US5723147A
(en)
*
|
1987-02-23 |
1998-03-03 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
|
US5807572A
(en)
*
|
1988-02-18 |
1998-09-15 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
|
WO1989008499A1
(fr)
*
|
1988-03-17 |
1989-09-21 |
Nippon Fine Chemical Co., Ltd. |
Liposome
|
|
US5422120A
(en)
*
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
US5230900A
(en)
*
|
1988-07-01 |
1993-07-27 |
The Biomembrane Institute |
Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells
|
|
JPH0720857B2
(ja)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
リポソームおよびその製法
|
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
|
US5043164A
(en)
*
|
1989-01-17 |
1991-08-27 |
The University Of Tennessee Research Corporation |
Blood-stable, cholesterol-free liposomes
|
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
|
JP2785981B2
(ja)
*
|
1989-11-20 |
1998-08-13 |
株式会社資生堂 |
乳化組成物
|
|
US5053406A
(en)
*
|
1989-12-13 |
1991-10-01 |
Glycomed, Inc. |
Compositions and methods for preventing and treating rotaviral infections
|
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
|
FR2661331A1
(fr)
*
|
1990-04-30 |
1991-10-31 |
Oreal |
Composition cosmetique ou dermopharmaceutique contenant des vesicules formees par un melange phospholipides/glycolipides.
|
|
DE4107153A1
(de)
*
|
1991-03-06 |
1992-09-10 |
Gregor Cevc |
Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
|
|
DE4107152C2
(de)
*
|
1991-03-06 |
1994-03-24 |
Gregor Cevc |
Präparate zur nichtinvasiven Verabreichung von Antidiabetica
|
|
US5298246A
(en)
*
|
1991-01-09 |
1994-03-29 |
Kanegafuchi Kagaku Kogyo Kabushiki Kaisha |
Stable pharmaceutical composition and method for its production
|
|
EP0609292A4
(en)
*
|
1991-10-18 |
1995-10-25 |
Wistar Inst |
Soluble variants of type i membrane proteins, and methods of using them.
|
|
WO1993020802A1
(en)
*
|
1992-04-09 |
1993-10-28 |
Northwestern University |
Acoustically reflective liposomes and methods to make and use the same
|
|
US5858399A
(en)
*
|
1992-04-09 |
1999-01-12 |
Northwestern University |
Acoustically reflective liposomes and methods to make and use the same
|
|
DE69332276T2
(de)
*
|
1992-04-10 |
2003-01-09 |
Hisamitsu Pharmaceutical Co., Inc. |
Liposomenzusammensetzung
|
|
US5455044A
(en)
*
|
1993-05-14 |
1995-10-03 |
Depotech Corporation |
Method for treating neurological disorders
|
|
US5534241A
(en)
*
|
1993-07-23 |
1996-07-09 |
Torchilin; Vladimir P. |
Amphipathic polychelating compounds and methods of use
|
|
US5863556A
(en)
*
|
1993-08-20 |
1999-01-26 |
Euro-Celtique, S.A. |
Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
|
|
US6217849B1
(en)
|
1993-09-29 |
2001-04-17 |
Bracco Research S.A. |
Liposome suspensions as blood pool imaging contrast agents
|
|
DE69424680T2
(de)
*
|
1993-10-25 |
2000-09-28 |
The Liposome Co.,Inc. |
Liposomale defensine
|
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
|
JP3002702B2
(ja)
*
|
1993-11-16 |
2000-01-24 |
スカイファーム インコーポレーテッド |
活性物質の制御放出を有する小胞
|
|
FR2712811B1
(fr)
*
|
1993-11-26 |
1996-01-05 |
Oreal |
Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
|
|
US5543152A
(en)
*
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5741516A
(en)
*
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5993850A
(en)
*
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
DK0785773T3
(da)
*
|
1994-10-14 |
2001-01-29 |
Liposome Co Inc |
Etherlipidliposomer og deres terapeutiske anvendelse
|
|
CA2187427A1
(en)
*
|
1995-02-24 |
1996-08-29 |
Bracco Research S.A. |
Liposome suspensions as blood pool imaging contrast agents
|
|
US6358915B1
(en)
|
1995-03-07 |
2002-03-19 |
George Washington University |
Methods for inhibiting metastasis
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
US6184201B1
(en)
*
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
|
US6153736A
(en)
|
1995-09-27 |
2000-11-28 |
The Liposome Company, Inc. |
Modified ether glyceroglycolipids
|
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
CA2234957C
(en)
|
1995-10-17 |
2006-12-19 |
Inge B. Henriksen |
Insoluble drug delivery
|
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
|
US5965159A
(en)
*
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
|
WO1997035561A1
(en)
|
1996-03-28 |
1997-10-02 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved liposome compositions
|
|
EP0906338B1
(en)
|
1996-04-12 |
2002-11-06 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
|
AU5571196A
(en)
*
|
1996-04-24 |
1997-11-12 |
Sdg, Inc. |
Improved masking of liposomes from res recognition
|
|
US6111081A
(en)
*
|
1996-05-31 |
2000-08-29 |
Baylor College Of Medicine |
Lactoferrin variants and uses thereof
|
|
US7309692B1
(en)
*
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
KR100190826B1
(ko)
*
|
1996-08-26 |
1999-06-01 |
강재헌 |
적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법
|
|
US5997899A
(en)
|
1996-10-01 |
1999-12-07 |
Skyepharma Inc. |
Method for producing liposomes with increased percent of compound encapsulated
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US6339069B1
(en)
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
|
EP0964690B1
(en)
*
|
1996-10-15 |
2003-07-09 |
The Liposome Company, Inc. |
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
|
US6037125A
(en)
*
|
1996-11-05 |
2000-03-14 |
Lexicon Genetics Incorporated |
Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
|
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
|
WO1999002139A1
(en)
*
|
1997-07-10 |
1999-01-21 |
Keith Baker |
Methods for universally distributing therapeutic agents to the brain
|
|
US20020115609A1
(en)
*
|
1997-07-14 |
2002-08-22 |
Hayat Onyuksel |
Materials and methods for making improved micelle compositions
|
|
US20050025819A1
(en)
*
|
1997-07-14 |
2005-02-03 |
Hayat Onyuksel |
Materials and methods for making improved micelle compositions
|
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
|
US6306432B1
(en)
|
1997-09-08 |
2001-10-23 |
Chiron Corporation |
High and low load formulations of IGF-I in multivesicular liposomes
|
|
ES2343767T3
(es)
*
|
1997-09-18 |
2010-08-09 |
Pacira Pharmaceuticals, Inc. |
Composiciones anestesicas liposomicas de liberacion sostenida.
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
JP4575592B2
(ja)
*
|
1997-11-14 |
2010-11-04 |
パシラ ファーマシューティカルズ インコーポレーテッド |
多小胞リポソームの製造
|
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
EP1190705A4
(en)
*
|
1999-06-24 |
2009-03-18 |
Kyowa Hakko Kogyo Kk |
METHOD FOR REGULATING THE LEAKAGE OF ENCAPSULATED MEDICINES IN LIPOSOMES
|
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
|
EP1246606A2
(en)
*
|
1999-12-30 |
2002-10-09 |
Judith K. Gwathmey |
Iron chelator delivery system
|
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
EP1267946A4
(en)
*
|
2000-02-28 |
2008-07-02 |
Genesegues Inc |
SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
|
|
US20030229393A1
(en)
*
|
2001-03-15 |
2003-12-11 |
Kutryk Michael J. B. |
Medical device with coating that promotes cell adherence and differentiation
|
|
JP5859179B2
(ja)
|
2000-03-15 |
2016-02-10 |
オーバスネイチ メディカル、インコーポレイテッド |
内皮細胞接着を促進するコーティング
|
|
US8088060B2
(en)
|
2000-03-15 |
2012-01-03 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
|
US20070055367A1
(en)
*
|
2000-03-15 |
2007-03-08 |
Orbus Medical Technologies, Inc. |
Medical device with coating that promotes endothelial cell adherence and differentiation
|
|
US8460367B2
(en)
*
|
2000-03-15 |
2013-06-11 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
|
US9522217B2
(en)
|
2000-03-15 |
2016-12-20 |
Orbusneich Medical, Inc. |
Medical device with coating for capturing genetically-altered cells and methods for using same
|
|
US20070141107A1
(en)
*
|
2000-03-15 |
2007-06-21 |
Orbusneich Medical, Inc. |
Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
|
|
WO2002060911A2
(en)
|
2000-12-11 |
2002-08-08 |
The Research Foundation Of The City University Of New York |
C-glucosyl ether lipids
|
|
US6759058B1
(en)
*
|
2001-04-25 |
2004-07-06 |
Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences |
Enteric-coated proliposomal formulations for poorly water soluble drugs
|
|
US8658202B2
(en)
|
2001-04-25 |
2014-02-25 |
Western University Of Health Sciences |
Coated drug delivery formulations
|
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
EP2270231A3
(en)
|
2001-10-09 |
2011-04-27 |
ISIS Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
CA2466103C
(en)
*
|
2001-11-02 |
2010-06-15 |
The Governors Of The University Of Alberta |
Micelle compositions containing pegylated phospholipids and a photosensitizer
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
EP1460898A4
(en)
*
|
2002-01-03 |
2006-05-24 |
Univ Texas |
WT1 ANTISENSE OLIGOS FOR THE INHIBITION OF BREAST CANCER
|
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
|
JP5578388B2
(ja)
*
|
2002-04-18 |
2014-08-27 |
オプコ ファーマシューティカルズ、エルエルシー |
中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
US20040213837A1
(en)
*
|
2002-08-05 |
2004-10-28 |
Sankaram Mantripragada |
Oil-core compositions for the sustained release of hydrophobic drugs
|
|
JP2005538186A
(ja)
|
2002-09-13 |
2005-12-15 |
レプリコール インコーポレーティッド |
非配列相補性の抗ウイルス性オリゴヌクレオチド
|
|
AU2003278957A1
(en)
|
2002-09-26 |
2004-04-23 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
|
EP2336318B1
(en)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
|
PT1435231E
(pt)
|
2002-12-31 |
2010-04-08 |
Zydus Bsv Pharma Private Ltd |
Lipossomas não peguilados de longo tempo de circulação
|
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
|
ATE477337T1
(de)
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
CN1918175A
(zh)
|
2003-09-29 |
2007-02-21 |
托皮根药品公司 |
治疗包括炎症状况的疾病的寡核苷酸组合物和方法
|
|
WO2005041870A2
(en)
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
|
CA2554818A1
(en)
|
2004-02-09 |
2005-08-25 |
Thomas Jefferson University |
Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
|
|
CA2563329C
(en)
*
|
2004-04-30 |
2016-01-26 |
Orbus Medical Technologies, Inc. |
Medical device with coating for capturing genetically-altered cells and methods for using same
|
|
ATE411006T1
(de)
*
|
2004-06-03 |
2008-10-15 |
Bracco Research Sa |
Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
|
|
US20060115455A1
(en)
*
|
2004-10-22 |
2006-06-01 |
Reed Kenneth C |
Therapeutic RNAi agents for treating psoriasis
|
|
MX2007005083A
(es)
*
|
2004-10-29 |
2007-10-03 |
Topigen Pharmaceuticals Inc |
Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
|
|
JP4990786B2
(ja)
*
|
2004-11-05 |
2012-08-01 |
イネックス ファーマシューティカルズ コーポレイション |
薬物リポソーム製剤を安定化するための組成物および方法
|
|
JP5264478B2
(ja)
*
|
2005-04-29 |
2013-08-14 |
ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド |
活性物質での細胞表面の装飾
|
|
US8287923B2
(en)
*
|
2005-06-10 |
2012-10-16 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating immune disorders
|
|
US9446017B2
(en)
|
2005-08-11 |
2016-09-20 |
Augusta University Research Institute, Inc. |
Compositions and methods for treating herpes simplex virus
|
|
CA2621441C
(en)
|
2005-09-12 |
2014-05-20 |
The Ohio State University Research Foundation |
Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
EP1951737A4
(en)
|
2005-11-01 |
2009-07-01 |
Alnylam Pharmaceuticals Inc |
INHIBITION OF INFLUENZA VIRUS REPLICATION BY RNA INTERFERENCE
|
|
US9149543B2
(en)
*
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
|
US20070178068A1
(en)
|
2005-12-22 |
2007-08-02 |
Reich Samuel J |
Compositions and methods for regulating complement system
|
|
EP2502630B1
(en)
|
2006-01-05 |
2015-03-11 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
|
CN101384273B
(zh)
|
2006-01-05 |
2013-07-10 |
俄亥俄州立大学研究基金会 |
胰腺内分泌和腺泡肿瘤中的微小rna表达异常
|
|
EP2484782B1
(en)
|
2006-01-05 |
2015-11-18 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
|
ES2448491T3
(es)
|
2006-03-02 |
2014-03-14 |
The Ohio State University Research Foundation |
Perfil de expresión de microARN asociado con cáncer de páncreas
|
|
EP2369013A1
(en)
|
2006-03-20 |
2011-09-28 |
The Ohio State University Research Foundation |
Micro-RNA fingerprints during human megakaryocytopoiesis
|
|
JP5160534B2
(ja)
*
|
2006-03-30 |
2013-03-13 |
ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク |
低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
|
|
WO2007123691A2
(en)
*
|
2006-03-30 |
2007-11-01 |
The Research Foundation Of State University Of New York |
Method for treating blood coagulation disorders
|
|
US7875288B2
(en)
*
|
2006-03-30 |
2011-01-25 |
The Research Foundation Of State University Of New York |
Method for treating blood coagulation disorders
|
|
CA2647728C
(en)
|
2006-03-31 |
2014-12-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
|
US20090130212A1
(en)
*
|
2006-05-15 |
2009-05-21 |
Physical Pharmaceutica, Llc |
Composition and improved method for preparation of small particles
|
|
CA2652770A1
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
|
AU2007252192B2
(en)
*
|
2006-05-19 |
2013-10-17 |
Topigen Pharmaceuticals Inc. |
Oligonucleotides affecting expression of phosphodiesterases
|
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
JP2009540011A
(ja)
*
|
2006-06-12 |
2009-11-19 |
エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． |
血管新生のｓｉＲＮＡ阻害のための組成物及び方法
|
|
EP2455493B1
(en)
|
2006-07-13 |
2014-01-08 |
The Ohio State University Research Foundation |
Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
|
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
|
WO2008091655A2
(en)
*
|
2007-01-23 |
2008-07-31 |
The Regents Of The University Of California |
Methods, compositions and device for directed and controlled heating and release of agents
|
|
JP5350360B2
(ja)
|
2007-03-29 |
2013-11-27 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
エボラ由来の遺伝子の発現を阻害するための組成物および方法
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
EP3127549B1
(en)
|
2007-06-22 |
2019-12-18 |
Children's Medical Center Corporation |
Methods and uses thereof of a fragment of saposin a
|
|
US7910722B2
(en)
|
2007-07-05 |
2011-03-22 |
Florida State University Research Foundation |
RNAi therapeutic for treatment of hepatitis C infection
|
|
CN101809169B
(zh)
|
2007-07-31 |
2013-07-17 |
俄亥俄州立大学研究基金会 |
通过靶向dnmt3a和dnmt3b恢复甲基化的方法
|
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
|
EP2173908B1
(en)
|
2007-08-03 |
2016-01-06 |
The Ohio State University Research Foundation |
Ultraconserved regions encoding ncrnas
|
|
WO2009023025A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Board Of Trustees Of Southern Illinois University |
Methods for treatment and prevention of ototoxicity by sirna
|
|
CA2926831A1
(en)
|
2007-08-22 |
2009-02-26 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
|
|
CA2698771A1
(en)
|
2007-09-06 |
2009-03-12 |
The Ohio State University Research Foundation |
Microrna signatures in human ovarian cancer
|
|
JP5731198B2
(ja)
|
2007-09-27 |
2015-06-10 |
イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． |
インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
|
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
CN103937876B
(zh)
|
2007-10-11 |
2016-08-17 |
俄亥俄州立大学研究基金会 |
用于诊断和治疗食管腺癌的方法和组合物
|
|
EP2848688A1
(en)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
|
CN102099474B
(zh)
|
2008-05-15 |
2014-05-28 |
托皮根药品公司 |
用于治疗炎症和赘生性细胞增殖的寡核苷酸
|
|
CN102056622B
(zh)
*
|
2008-06-05 |
2016-04-06 |
免疫疫苗技术有限公司 |
包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
|
|
SG196769A1
(en)
|
2008-08-25 |
2014-02-13 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
|
EP3208337A1
(en)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions for combined inhibition of mutant egfr and il-6 expression
|
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
|
WO2010036962A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
US8470792B2
(en)
|
2008-12-04 |
2013-06-25 |
Opko Pharmaceuticals, Llc. |
Compositions and methods for selective inhibition of VEGF
|
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
JP2012515532A
(ja)
|
2009-01-20 |
2012-07-12 |
ラモット アット テル アビブ ユニバーシティ， リミテッド |
Ｍｉｒ−２１プロモーター駆動性標的がん治療
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
US8524784B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
|
US8524783B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
|
IT1398857B1
(it)
|
2009-06-10 |
2013-03-21 |
Univ Padova |
Coniugati polimerici fosfolipidi
|
|
EP2464336A4
(en)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
|
|
US8828656B2
(en)
|
2009-08-31 |
2014-09-09 |
University Of Bremen |
Microrna-based methods and compositions for the diagnosis, prognosis and treatment of tumor involving chromosomal rearrangements
|
|
KR20120082906A
(ko)
|
2009-09-30 |
2012-07-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
BR112012009801A8
(pt)
|
2009-10-30 |
2016-08-30 |
Cns Therapeutics Inc |
Polipeptídeo neurturina e variante de neurturina
|
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
|
WO2011069155A1
(en)
*
|
2009-12-04 |
2011-06-09 |
Opko Ophthalmics, Llc |
Compositions and methods for inhibition of vegf
|
|
EP2513137B1
(en)
|
2009-12-17 |
2018-02-28 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
|
CA2792679C
(en)
|
2010-03-09 |
2019-11-12 |
Mucosal Vaccine Thechnologies Llc |
A novel mucosal vaccination approach for herpes simplex virus type-2
|
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
|
AU2011237630B2
(en)
|
2010-04-06 |
2016-01-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
|
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
|
US9944671B2
(en)
|
2010-06-02 |
2018-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
PH12013500064A1
(en)
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
WO2012075337A2
(en)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
|
SI2670411T1
(sl)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
|
|
MX360349B
(es)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
|
EP2714906A1
(en)
|
2011-06-01 |
2014-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for adjusting expression of mitochondrial genome by microrna
|
|
SG10201805199RA
(en)
|
2011-06-02 |
2018-07-30 |
Harvard College |
Methods and Uses for Ex Vivo Tissue Culture Systems
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
|
AU2012271413B2
(en)
|
2011-06-17 |
2017-07-13 |
President And Fellows Of Harvard College |
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
|
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
|
KR20230084331A
(ko)
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
|
EP3444348A1
(en)
|
2011-06-21 |
2019-02-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
EP2723865B1
(en)
|
2011-06-21 |
2019-03-27 |
Alnylam Pharmaceuticals, Inc. |
METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT
|
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
CN103765212A
(zh)
|
2011-06-27 |
2014-04-30 |
杰克逊实验室 |
治疗癌症和自体免疫性疾病的方法和组合物
|
|
EP2543370A1
(en)
|
2011-07-06 |
2013-01-09 |
Georgia Health Sciences University Research Institute, Inc. |
Compositions and Methods for Treating Herpes Simplex Virus
|
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
CN113876945A
(zh)
|
2011-10-06 |
2022-01-04 |
免疫疫苗技术有限公司 |
包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
|
|
EP2766500A4
(en)
|
2011-10-14 |
2015-10-14 |
Univ Ohio State |
METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
|
|
WO2013060894A1
(en)
|
2011-10-27 |
2013-05-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of atherosclerosis
|
|
CA2860226C
(en)
|
2011-12-22 |
2022-10-18 |
Randolph S. Watnick |
Saposin-a derived peptides and uses thereof
|
|
WO2013119602A1
(en)
|
2012-02-06 |
2013-08-15 |
President And Fellows Of Harvard College |
Arrdc1-mediated microvesicles (armms) and uses thereof
|
|
ES2762873T3
(es)
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
|
WO2013148283A1
(en)
|
2012-03-30 |
2013-10-03 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EP2836219A1
(en)
|
2012-04-10 |
2015-02-18 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of nonalcoholic steatohepatitis
|
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
KR102310697B1
(ko)
|
2012-11-20 |
2021-10-12 |
스펙트럼 파마슈티컬즈 인크 |
치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
|
|
KR102096014B1
(ko)
|
2012-12-05 |
2020-04-03 |
알닐람 파마슈티칼스 인코포레이티드 |
PCSK9 iRNA 조성물 및 그 사용 방법
|
|
EP2929035A1
(en)
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
|
DK2941269T3
(da)
|
2013-01-07 |
2021-01-11 |
Mucosal Vaccine Tech Llc |
Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
|
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
|
ME03043B
(me)
|
2013-03-14 |
2018-10-20 |
Alnylam Pharmaceuticals Inc |
Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
|
|
CN111254145A
(zh)
|
2013-03-14 |
2020-06-09 |
Ionis制药公司 |
用于调节tau表达的组合物和方法
|
|
EP2970940B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
EP2968586B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Cftr mrna compositions and related methods and uses
|
|
EP4614148A3
(en)
|
2013-03-15 |
2025-12-17 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
|
TW201515650A
(zh)
|
2013-05-06 |
2015-05-01 |
艾爾妮蘭製藥公司 |
遞送經脂質調配之核酸分子之劑量及方法
|
|
KR102463973B1
(ko)
|
2013-05-22 |
2022-11-07 |
알닐람 파마슈티칼스 인코포레이티드 |
ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
|
|
EA201592225A1
(ru)
|
2013-05-22 |
2016-04-29 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2015006228A1
(en)
|
2013-07-08 |
2015-01-15 |
The University Of Utah Research Foundation |
Methods for treatment of and prophylaxis against inflammatory disorders
|
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
SG11201602631XA
(en)
|
2013-10-04 |
2016-05-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
MX2016005239A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
|
US11224642B2
(en)
|
2013-10-22 |
2022-01-18 |
Translate Bio, Inc. |
MRNA therapy for argininosuccinate synthetase deficiency
|
|
WO2015086828A1
(en)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
CA2931090A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
|
AU2015217301A1
(en)
|
2014-02-11 |
2016-08-25 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
|
JP6571679B2
(ja)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの精製方法
|
|
BR122020023687B1
(pt)
|
2014-05-22 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc |
Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
|
EP3188716B1
(en)
|
2014-09-03 |
2022-10-26 |
GeneSegues, Inc. |
Therapeutic nanoparticles and related compositions, methods and systems
|
|
AR101753A1
(es)
|
2014-09-03 |
2017-01-11 |
Boehringer Ingelheim Int |
COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
SG11201703638XA
(en)
|
2014-11-10 |
2017-06-29 |
Alnylam Pharmaceuticals Inc |
Hepatitis b virus (hbv) irna compositions and methods of use thereof
|
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
EP3234141A4
(en)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016118476A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
US10487324B2
(en)
|
2015-02-25 |
2019-11-26 |
Washington University |
Methods to detect motor neuron disease comprising micro-RNAs
|
|
US10302629B2
(en)
|
2015-03-30 |
2019-05-28 |
University Of Maryland, Baltimore |
Compositions and methods for treating cancer by rational targeting of protein translation
|
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
|
KR20250107273A
(ko)
|
2015-05-06 |
2025-07-11 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
EP3316685A4
(en)
|
2015-07-02 |
2019-03-13 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized Pharmaceutical Compositions
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
DK3324980T3
(da)
|
2015-07-17 |
2022-02-14 |
Alnylam Pharmaceuticals Inc |
Multimålrettede enkeltenhedskonjugater
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
UA125433C2
(uk)
|
2015-07-23 |
2022-03-09 |
Бьорінґер Інґельхайм Інтернаціональ Ґмбх |
Націлена на іl-23а і фактор активації в-лімфоцитів (baff) сполука та її застосування
|
|
CN108368507B
(zh)
|
2015-09-02 |
2022-03-22 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
SG10202104041PA
(en)
|
2015-10-23 |
2021-06-29 |
Harvard College |
Nucleobase editors and uses thereof
|
|
EP3377630A4
(en)
|
2015-11-16 |
2020-01-01 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法
|
|
JP6944942B2
(ja)
|
2016-02-02 |
2021-10-06 |
オリックス ファーマシューティカルズ，インコーポレーテッド |
ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
|
|
US10435682B2
(en)
|
2016-02-19 |
2019-10-08 |
University Of South Florida |
Arginine deiminase gene therapy for disordered proteins
|
|
EA201892784A1
(ru)
|
2016-06-08 |
2019-05-31 |
Пол Стенмарк |
Сконструированные ботулинические нейротоксины
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
UA125965C2
(uk)
|
2016-07-08 |
2022-07-20 |
Чілдренс Медікал Сентр Корпорейшн |
Новий ботулінічний нейротоксин та його похідні
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11202818B2
(en)
|
2016-09-14 |
2021-12-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
|
ES2963428T3
(es)
|
2016-09-29 |
2024-03-27 |
Biogen Ma Inc |
Compuestos y métodos para reducir la expresión de Tau
|
|
WO2018067546A1
(en)
|
2016-10-03 |
2018-04-12 |
President And Fellows Of Harvard College |
Delivery of therapeutic rnas via arrdc1-mediated microvesicles
|
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CA3048479A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Gene editing of pcsk9
|
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
SG11201909572QA
(en)
|
2017-04-18 |
2019-11-28 |
Alnylam Pharmaceuticals Inc |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
|
WO2018204918A1
(en)
|
2017-05-05 |
2018-11-08 |
Ardelyx, Inc. |
Treatment of hepatic disorders
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
KR20200024793A
(ko)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
EP3661522A2
(en)
|
2017-08-03 |
2020-06-10 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
EP3687566A2
(en)
|
2017-09-29 |
2020-08-05 |
Children's Medical Center Corporation |
A neurotoxin-like toxin and uses thereof
|
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019136310A2
(en)
|
2018-01-05 |
2019-07-11 |
University Of South Florida |
Novel compounds for the treatment of neurodegenerative diseases
|
|
WO2019168953A1
(en)
|
2018-02-27 |
2019-09-06 |
President And Fellows Of Harvard College |
Evolved cas9 variants and uses thereof
|
|
US10507226B1
(en)
|
2018-05-02 |
2019-12-17 |
University Of South Florida |
N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease
|
|
KR20250133482A
(ko)
|
2018-05-11 |
2025-09-05 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
CN112805379B
(zh)
|
2018-08-03 |
2024-08-20 |
比姆医疗股份有限公司 |
多效应核碱基编辑器和使用其修饰核酸靶序列的方法
|
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
CN118421617A
(zh)
|
2018-08-24 |
2024-08-02 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
|
IL280935B2
(en)
*
|
2018-08-24 |
2025-04-01 |
Flagship Pioneering Innovations Vi Llc |
Modified plant-based courier packaging and its uses
|
|
US20240173430A1
(en)
|
2018-09-05 |
2024-05-30 |
The Broad Institute, Inc. |
Base editing for treating hutchinson-gilford progeria syndrome
|
|
WO2020060986A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
WO2020076173A1
(en)
|
2018-09-21 |
2020-04-16 |
Universidade De Coimbra |
Nanodelivery tissue targeting at low systemic exposures and methods thereof
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
EP3883592A1
(en)
|
2018-11-21 |
2021-09-29 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
JP2022513159A
(ja)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド |
Ｒｎａを調節する方法
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
JP2022523779A
(ja)
|
2019-03-12 |
2022-04-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
癌を処置するための方法および組成物
|
|
EP3942043A2
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US20220211741A1
(en)
|
2019-04-18 |
2022-07-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and prognosis of cancer
|
|
EP3973054A1
(en)
|
2019-05-20 |
2022-03-30 |
The Broad Institute Inc. |
Aav delivery of nucleobase editors
|
|
WO2020252257A1
(en)
|
2019-06-12 |
2020-12-17 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
|
CN114258398A
(zh)
|
2019-06-13 |
2022-03-29 |
总医院公司 |
工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
|
|
EP4010474A1
(en)
|
2019-08-08 |
2022-06-15 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
AU2020345830A1
(en)
|
2019-09-09 |
2022-03-24 |
Beam Therapeutics Inc. |
Novel CRISPR enzymes, methods, systems and uses thereof
|
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
JP2022550130A
(ja)
|
2019-09-26 |
2022-11-30 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
最小アレスチンドメイン含有蛋白質１（ａｒｒｄｃ１）コンストラクト
|
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
CN114728018B
(zh)
|
2019-11-01 |
2024-07-19 |
阿尔尼拉姆医药品有限公司 |
亨廷顿(HTT)iRNA药剂组合物及其使用方法
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
CN121759549A
(zh)
|
2019-12-03 |
2026-03-31 |
比姆医疗股份有限公司 |
合成向导rna、其组合物、方法和用途
|
|
TWI897902B
(zh)
|
2019-12-13 |
2025-09-21 |
美商阿尼拉製藥公司 |
人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
|
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
EP4100519A2
(en)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
EP4707398A2
(en)
|
2020-02-05 |
2026-03-11 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
|
MX2022009763A
(es)
|
2020-02-10 |
2022-09-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
US12534731B2
(en)
|
2020-04-01 |
2026-01-27 |
Alnylam Pharmaceuticals, Inc. |
Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
|
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
IL297130A
(en)
|
2020-04-07 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing scn9a expression
|
|
WO2021222065A1
(en)
|
2020-04-27 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
|
BR112022022603A2
(pt)
|
2020-05-08 |
2023-01-17 |
Broad Inst Inc |
Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
EP4157264A4
(en)
|
2020-05-27 |
2024-06-19 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR CELL TRANSDIFFERENTIATION
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
US20230203496A1
(en)
|
2020-06-09 |
2023-06-29 |
Alnylam Pharmaceuticals, Inc. |
Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
|
|
IL299771A
(en)
|
2020-07-10 |
2023-03-01 |
Inst Nat Sante Rech Med |
Methods and compounds for the treatment of epilepsy
|
|
CN116670154A
(zh)
|
2020-07-24 |
2023-08-29 |
总医院公司 |
增强的病毒样颗粒及使用其递送至细胞的方法
|
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
|
IL301306A
(en)
|
2020-09-16 |
2023-05-01 |
Harvard College |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
|
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
JP2023554540A
(ja)
|
2020-10-28 |
2023-12-27 |
ザ チルドレンズ メディカル センター コーポレーション |
切断型修飾組換えａｄａｍｔｓ１３およびその使用
|
|
EP4256053A1
(en)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12151024B2
(en)
|
2021-01-22 |
2024-11-26 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12129470B2
(en)
|
2021-02-09 |
2024-10-29 |
The Texas A&M University System |
Methods and compositions related to RNA-targeted Rho small GTPase RND3/RhoE therapy
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
WO2022178307A1
(en)
|
2021-02-19 |
2022-08-25 |
Beam Therapeutics Inc. |
Recombinant rabies viruses for gene therapy
|
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
CN117529555A
(zh)
|
2021-03-23 |
2024-02-06 |
比姆医疗股份有限公司 |
新颖crispr酶、方法、系统及其用途
|
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
|
WO2022221699A1
(en)
|
2021-04-16 |
2022-10-20 |
Beam Therapeutics, Inc. |
Genetic modification of hepatocytes
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
WO2022256578A2
(en)
|
2021-06-02 |
2022-12-08 |
Beam Therapeutics Inc. |
Circular guide rnas for crispr/cas editing systems
|
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
|
US20250034564A1
(en)
|
2021-06-29 |
2025-01-30 |
Korro Bio, Inc. |
Methods and Compositions for ADAR-Mediated Editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
EP4373931A1
(en)
|
2021-07-23 |
2024-05-29 |
Beam Therapeutics Inc. |
Guide rnas for crispr/cas editing systems
|
|
JP2024528701A
(ja)
|
2021-07-23 |
2024-07-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法
|
|
MX2024002440A
(es)
|
2021-08-31 |
2024-03-08 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
|
|
CA3230629A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
GB2627096A
(en)
|
2021-10-14 |
2024-08-14 |
Pacira Pharmaceuticals Inc |
Bupivacaine multivesicular liposome formulations and uses thereof
|
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
CA3238700A1
(en)
|
2021-11-23 |
2022-11-23 |
Philippe Duchateau |
New tale protein scaffolds with improved on-target/off-target activity ratios
|
|
US20250064979A1
(en)
|
2021-12-03 |
2025-02-27 |
The Broad Institute, Inc. |
Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
|
|
WO2023102537A2
(en)
|
2021-12-03 |
2023-06-08 |
The Broad Institute, Inc. |
Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
|
|
JP2024546841A
(ja)
|
2021-12-17 |
2024-12-26 |
ビーム セラピューティクス インク． |
新規ｃｒｉｓｐｒ酵素、方法、システム、及びそれらの使用
|
|
KR20240126870A
(ko)
|
2021-12-22 |
2024-08-21 |
캠프4 테라퓨틱스 코포레이션 |
조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
|
EP4504925A1
(en)
|
2022-04-04 |
2025-02-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
|
WO2023205687A1
(en)
|
2022-04-20 |
2023-10-26 |
The Broad Institute, Inc. |
Improved prime editing methods and compositions
|
|
CN120456933A
(zh)
|
2022-04-28 |
2025-08-08 |
布罗德研究所股份有限公司 |
编码碱基编辑器的aav载体及其用途
|
|
CA3255335A1
(en)
|
2022-05-27 |
2023-11-30 |
President And Fellows Of Harvard College |
IMPROVED MITOCHONDRIAL BASIS EDITORS AND MITOCHONDRIAL DNA EDITING METHODS
|
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
|
AU2023283551A1
(en)
|
2022-06-10 |
2024-12-19 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
|
EP4573191A1
(en)
|
2022-08-16 |
2025-06-25 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
|
TW202424193A
(zh)
|
2022-09-15 |
2024-06-16 |
美商艾拉倫製藥股份有限公司 |
第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
|
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|
|
WO2024077267A1
(en)
|
2022-10-07 |
2024-04-11 |
The Broad Institute, Inc. |
Prime editing methods and compositions for treating triplet repeat disorders
|
|
JP2025540101A
(ja)
|
2022-12-01 |
2025-12-11 |
キャンプ４ セラピューティクス コーポレイション |
調節ｒｎａを標的とするアンチセンスオリゴヌクレオチドを用いたｓｙｎｇａｐ１遺伝子転写の調節
|
|
WO2024138087A2
(en)
|
2022-12-23 |
2024-06-27 |
The Broad Institute, Inc. |
Methods and compositions for modulating cellular factors to increase prime editing efficiencies
|
|
EP4652271A1
(en)
|
2023-01-18 |
2025-11-26 |
The Broad Institute, Inc. |
Base editing-mediated readthrough of premature termination codons (bert)
|
|
EP4652272A1
(en)
|
2023-01-18 |
2025-11-26 |
The Broad Institute Inc. |
Prime editing-mediated readthrough of premature termination codons (pert)
|
|
AU2024217843A1
(en)
|
2023-02-09 |
2025-07-31 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
WO2024168147A2
(en)
|
2023-02-09 |
2024-08-15 |
The Broad Institute, Inc. |
Evolved recombinases for editing a genome in combination with prime editing
|
|
WO2024206125A1
(en)
|
2023-03-24 |
2024-10-03 |
The Broad Institute, Inc. |
Use of prime editing for treating sickle cell disease
|
|
EP4716740A1
(en)
|
2023-05-23 |
2026-04-01 |
The Broad Institute, Inc. |
Evolved and engineered prime editors with improved editing efficiency
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
IL326321A
(en)
|
2023-08-04 |
2026-04-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for treating CTNNB1-related disorders
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2025059215A1
(en)
|
2023-09-12 |
2025-03-20 |
Aadigen, Llc |
Methods and compositions for treating or preventing cancer
|
|
WO2025061810A1
(en)
|
2023-09-20 |
2025-03-27 |
Institut National de la Santé et de la Recherche Médicale |
Use of a mirna inhibitor for the treatment of osteogenesis imperfecta
|
|
WO2025064678A2
(en)
|
2023-09-20 |
2025-03-27 |
The Broad Institute, Inc. |
Prime editing-mediated readthrough of frameshift mutations (perf)
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025106685A1
(en)
|
2023-11-15 |
2025-05-22 |
Slate Bio, Inc. |
Interleukin-2 superkine and interleukin-33, compositions and uses thereof
|
|
WO2025106677A1
(en)
|
2023-11-15 |
2025-05-22 |
Slate Bio, Inc. |
Bifunctional il-2 and il-33 proteins for treating autoimmune disease
|
|
WO2025106663A1
(en)
|
2023-11-15 |
2025-05-22 |
Slate Bio, Inc. |
Interleukin-33 variants, compositions and uses thereof
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025188687A1
(en)
|
2024-03-04 |
2025-09-12 |
Beam Therapeutics Inc. |
Stable rna compositions with stem loop, and methods thereof
|
|
US12246092B1
(en)
|
2024-05-20 |
2025-03-11 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12251472B1
(en)
|
2024-05-20 |
2025-03-18 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12251468B1
(en)
|
2024-05-20 |
2025-03-18 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
WO2025255388A1
(en)
|
2024-06-05 |
2025-12-11 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2025259863A1
(en)
|
2024-06-12 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Thermostable ribonuclease r for circular rna purification
|
|
WO2026024856A2
(en)
|
2024-07-23 |
2026-01-29 |
The Broad Institute, Inc. |
Compositions and methods for production of double-stranded dna in cells for programmable gene integration
|
|
WO2026050243A1
(en)
|
2024-08-26 |
2026-03-05 |
Korro Bio, Inc. |
Galnac conjugated oligonucleotides for rna editing
|
|
WO2026046724A1
(en)
|
2024-08-30 |
2026-03-05 |
Cellectis Sa |
Tale protein scaffolds involving fusions of monopartite and bipartite nls
|
|
WO2026072421A2
(en)
|
2024-09-27 |
2026-04-02 |
The Broad Institute, Inc. |
Base editing methods and compositions for editing prnp in the treatment of prion disease
|